drugset / Trial / NCT02811679
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).
Timeline
- Start
- 2016-08
- Primary completion
- 2020-01-27
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 112 ug | Intravenous |